Prudential PLC Raises Position in Medpace Holdings, Inc. $MEDP

Prudential PLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 113.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,360 shares of the company’s stock after purchasing an additional 7,637 shares during the period. Prudential PLC’s holdings in Medpace were worth $8,065,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. AQR Capital Management LLC lifted its position in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the last quarter. Norges Bank bought a new position in Medpace during the fourth quarter valued at $102,156,000. Goldman Sachs Group Inc. raised its stake in shares of Medpace by 92.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after acquiring an additional 166,654 shares during the period. Finally, Wasatch Advisors LP raised its stake in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP stock opened at $454.25 on Friday. The company has a market capitalization of $12.97 billion, a P/E ratio of 28.55, a P/E/G ratio of 2.33 and a beta of 1.18. The company’s 50-day simple moving average is $456.73 and its two-hundred day simple moving average is $508.93. Medpace Holdings, Inc. has a one year low of $294.07 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MEDP. Robert W. Baird dropped their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Mizuho set a $582.00 price objective on shares of Medpace in a research report on Wednesday, February 11th. Royal Bank Of Canada decreased their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Truist Financial dropped their target price on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Finally, Barclays cut their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $467.08.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.